Shots:

• The companies collaborate to develop IN-006 (an inhaled form of regdanvimab) to treat patients with COVID-19. The results are expected in 2022
• Inhalon will start a P-I study of nebulized regdanvimab in the next few mos. & plans to complete at the end of 2021 while the study is funded by $7M from the US AMRDC. Celltrion has completed a P-III study which demonstrates that regdanvimab reduced the risk of hospitalization or death by 72% for patients with COVID-19 & 70% for all patients
• Additionally- in vitro & in vivo pre-clinical studies showed that CT-P59 strongly binds to SARS-CoV-2 RBD & neutralizes wild type & mutant variants of concern including Alpha variant

  | Ref: PR Newswire | Image: Celltrion